Pancreatic cancer accounts for just 3% of cancers diagnosed in the United States each year, yet it is on track to become the second leading cause of cancer-related deaths by 2030. To change this trajectory, Lustgarten’s research strategy is focused on the areas of greatest need for patients: earlier detection, new drug development and personalized medicine. To ensure research progress turns into clinical advances, we concentrate on the transition from the bench to the bedside—translating our understanding of the underlying biology of pancreatic cancer into clinical testing opportunities and realities for patients.